| Literature DB >> 30745895 |
Anny Camelo-Castillo1, Desirée Henares1,2, Pedro Brotons1,2, Antonio Galiana3, Juan Carlos Rodríguez3, Alex Mira2,4, Carmen Muñoz-Almagro1,2,5.
Abstract
Background and Aims: The risk of suffering from some infectious diseases can be related to specific microbiota profiles. Specifically, the nasopharyngeal microbiota could play a role as a risk or protective factor in the development of invasive disease caused by S. pneumoniae. Methodology: We analyzed the nasopharyngeal microbiota of children with invasive pneumococcal disease (IPD) and that of healthy controls matched by age, sex, and seasonality from Catalonia, Spain. Epidemiological, microbiological and clinical variables were considered to compare microbiota profiles, analyzed by sequencing the V1-V4 region of the 16S rRNA gene.Entities:
Keywords: Dolosigranulum; Streptococcus pneumoniae; children; invasive pneumococcal disease; nasopharyngeal microbiota
Year: 2019 PMID: 30745895 PMCID: PMC6360994 DOI: 10.3389/fmicb.2019.00011
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Epidemiological and microbiological characteristics of study groups.
| Age, months (Md, IQR) | 43.0 (20.8–60.2) | 42.6 (31.6–58.9) | 0.72 |
| Gender, male | 16 (57.1) | 16 (57.1) | 1.00 |
| Influenza season | 12 (42.9) | 14 (50.0) | 0.59 |
| Race, Caucasian | 23 (82.1) | 25 (89.3) | 0.71 |
| Birth weight, gr (Mean, SD) | 3,143 (626) | 3,298 (579) | 0.34 |
| Gestational age, weeks (Mean, SD) | 38.5 (2.3) | 38.8 (2.0) | 0.67 |
| Delivery type, C–section | 7 (28.0) | 10 (38.5) | 0.43 |
| Breastfeeding | 23 (82.1) | 19 (67.9) | 0.22 |
| Breastfeeding duration ≥6 months | 9 (39.1) | 13 (68.4) | 0.06 |
| Breastfeeding duration, months (Md, IQR) | 4 (1–7) | 6 (4–10) | 0.19 |
| Day-care attendance | 25 (89.3) | 23 (82.1) | 0.45 |
| Shared bedroom | 13 (61.9) | 12 (44.4) | 0.23 |
| Parental smoking | 11 (42.3) | 13 (46.4) | 0.76 |
| Vaccinated against influenza | 1 (3.6) | 0 (0.0) | 1.00 |
| Vaccinated against pneumococcal disease | 17 (60.7) | 19 (67.9) | 0.58 |
| PCV13 vaccinated | 14 (82.4) | 17 (89.5) | 0.42 |
| Respiratory infection in the previous 30 days | 13 (46.4) | 13 (48.1) | 0.90 |
| Sp detection in NP sample by PCR | 18 (64.3) | 16 (57.1) | 0.58 |
| High-attack rate Sp serotype in NP sample | 10 (55.5) | 2 (12.5) | |
| PCV13 serotype coverage in NP sample | 11 (61.1) | 2 (12.5) | |
| Viral detection in NP sample by PCR | 17 (60.7) | 14 (50.0) | 0.42 |
| Rinovirus | 10 (35.7) | 10 (35.7) | 1.00 |
| Adenovirus | 4 (14.3) | 4 (14.3) | 1.00 |
| Parainfluenza virus | 2 (7.1) | 1 (3.6) | 1.00 |
| Respiratory siyncytial virus | 2 (7.1) | 0 (0.0) | 0.49 |
| Coronavirus | 1 (3.6) | 2 (7.1) | 1.00 |
| Enterovirus | 1 (3.6) | 0 (0.0) | 1.00 |
| Bocavirus | 1 (3.6) | 0 (0.0) | 1.00 |
| Influenza A virus | 2 (7.1) | 0 (0.0) | 0.49 |
| Influenza B virus | 0 (0.0) | 1 (3.6) | 1.00 |
| Multiple respiratory viral infection | 5 (29.4) | 4 (28.6) | 1.00 |
Results expressed as counts (%) unless stated otherwise.
Md, median; IQR, interquartile range; SD, standard deviation; PCV13, 13-valent pneumococcal conjugate vaccine; PICU, pediatric intensive care unit.
missing values.
according to WHO recommendations.
The bold values means statistically significant associations with p-values < 0.05.
Figure 1Rarefaction curves of nasopharyngeal samples in patients with invasive pneumococcal disease (cases) and healthy children (controls). The horizontal axis shows the number of reads (sequencing effort) obtained by pyrosequencing the 16S rRNA gene. The vertical axis shows the number (mean ± S.E.) of operational taxonomic units (OTUs) at a level of 97% (estimated mean number of bacterial species).
Figure 2Bacterial taxonomic composition of nasopharyngeal samples in cases and controls. (A) Graphs show the mean proportion of the most frequent bacterial genera as inferred by PCR amplification and pyrosequencing of the 16S rRNA gene. The mean proportions were calculated based on 1,000 sequences per sample. Those bacteria at a proportion lower than 1% are indicated as “Others” and were particularly abundant in cases. (B) Shows a description of those low-frequency bacteria in patients with IPD, which include many oral organisms (bacteria at a proportion <0.2% are not shown). (C) A Linear Discriminant Analysis Effect Size (LEfSe) analysis shows those bacteria with significantly different levels (α = 0.05) between cases and controls.
Bacterial species identified in the present study.
| 51.08% | 91.17% | ||
| 23.10% | 2.82% | ||
| 7.02% | 0.51% | ||
| sp | 6.62% | 1.07% | |
| uncultured sp | 5.40% | 1.49% | |
| 3.19% | 0.13% | ||
| sp. oral clone | 1.84% | 0.64% | |
| 0.74% | – | ||
| 0.41% | 0.77% | ||
| 0.22% | – | ||
| 0.12% | – | ||
| 0.10% | – | ||
| 0.07% | 0.47% | ||
| 0.02% | 0.94% | ||
| 83.26% | 84.17% | ||
| uncultured sp | 16.74% | 15.83% | |
| 80.30% | 99,65% | ||
| uncultured sp | 11.77% | 0,08% | |
| sp | 6.81% | 0,03% | |
| 1.02% | 0,09% | ||
| 0.11% | 0,10% | ||
| 94.89% | 79.71% | ||
| 2.93% | 8.30% | ||
| 2.14% | 4.46% | ||
| 0.04% | 0.40% | ||
| – | 7.14% | ||
| uncultured sp | 34.54% | 60.00% | |
| 15.70% | – | ||
| sp | 12.80% | 20.00% | |
| sp. oral clone | 12.32% | – | |
| 9.90% | – | ||
| 3.86% | 20.00% | ||
| 3.38% | – | ||
| 2.90% | – | ||
| 1.69% | – | ||
| 0.72% | – | ||
| uncultured sp | 39,94% | 24.00% | |
| 29,49% | 24.00% | ||
| sp | 14,23% | 8.00% | |
| 7,37% | 24.00% | ||
| sp. oral taxon | 6,67% | 20.00% | |
| 2,24% | – | ||
| uncultured sp | 71.93% | 56.25% | |
| sp. | 14.91% | 18,75% | |
| sp | 13.16% | 25.00% | |
| 65,40% | 9.67% | ||
| sp | 11,16% | 47.12% | |
| 7,07% | 0.05% | ||
| uncultured sp | 6,51% | 2.23% | |
| 3,35% | – | ||
| 2,51% | – | ||
| 1,95% | – | ||
| 1,40% | – | ||
| 0,28% | – | ||
| 0,28% | – | ||
| – | 40.89% |
Data indicate percentages of 16S rRNA reads from a given genus with a hit against each species. Frequencies of each genera are shown in Figure .
Figure 3Principal Coordinates Analysis (PCoA) of all 56 nasopharyngeal samples according to bacterial composition. Data include IPD patients (red-dots) and healthy controls (blue dots). PCoAs were performed with weighted UniFrac analysis with clustering at the species taxonomic level (97% sequence identity) with 1,000 reads per sample. The taxonomic composition (proportion of bacterial genera) of the 3 microbiota types (“nasopharyngeal-types”) is shown to the right. Data in (A–C) were obtained from 1,000 randomly selected sequences per sample.
Figure 4Correlations between the frequency of dominant bacteria in the three nasopharyngeal microbiota types. Data show potential negative associations, as they followed significant hyperbolic regressions.
Epidemiological, microbiological, immunological, and clinical characteristics by microbiota type.
| Case group | 5 (17.9) | 14 (50.0) | 9 (32.1) | |
| Age, months (Md, IQR) | 40.8 (20.8–80.3) | 41.4 (32.1–56.6) | 44.4 (29.5–61.4) | 0.95 |
| Gender, male | 8 (53.3) | 8 (47.1) | 16 (66.7) | 0.43 |
| Influenza season | 6 (40.0) | 6 (35.3) | 14 (58.3) | 0.29 |
| Race, Caucasian | 11 (73.3) | 16 (94.1) | 21 (87.5) | 0.26 |
| Birth weight, gr (Mean, SD) | 3,147 (689) | 3,329 (749) | 3,198 (428) | 0.68 |
| Gestational age, weeks (Mean, SD) | 38.1 (2.3) | 38.6 (2.6) | 39.7 (1.7) | 0.43 |
| Delivery type, C-section | 6 (42.9) | 4 (28.6) | 7 (30.4) | 0.75 |
| Breastfeeding | 13 (86.7) | 13 (76.5) | 16 (66.7) | 0.43 |
| Breastfeeding in controls | 9 (90.0) | 1 (33.3) | 9 (60.0) | 0.10 |
| Breastfeeding duration ≥ 6 months | 7 (53.9) | 7 (53.9) | 8 (50.0) | 0.97 |
| Breastfeeding duration, months (Md, IQR) | 6 (3–10) | 6 (3–12) | 5.5 (1.5–7) | 0.67 |
| Day-care attendance | 13 (86.7) | 16 (94.1) | 19 (79.2) | 0.40 |
| Shared bedroom | 5 (33.3) | 7 (58.3) | 13 (61.9) | 0.21 |
| Parental smoking | 8 (53.3) | 6 (40.0) | 10 (41.7) | 0.71 |
| Vaccinated against influenza | 0 (0.0) | 0 (0.0) | 1 (4.2) | 1.00 |
| Vaccinated against pneumococcal disease | 9 (60.0) | 13 (46.5) | 14 (58.3) | 0.45 |
| PCV13 vaccinated | 7 (77.8) | 11 (84.6) | 13 (92.9) | 0.61 |
| Respiratory infection in the previous 30 days | 6 (42.9) | 5 (31.3) | 15 (68.2) | 0.07 |
| Sp detection in NP sample by PCR | 7 (46.6) | 9 (52.9) | 18 (75.0) | 0.16 |
| High-attack rate Sp serotype in NP sample | 3 (42.9) | 3 (33.3) | 6 (33.3) | 0.90 |
| PCV13 serotype coverage in NP sample | 3 (42.9) | 4 (44.4) | 6 (33.3) | 0.81 |
| Viral detection in NP sample by PCR | 7 (46.7) | 8 (47.1) | 16 (66.7) | 0.34 |
| Multiple respiratory viral infection | 2 (28.6) | 3 (37.5) | 4 (25.0) | 0.82 |
| White blood count, 103cells/mm3 | 24.6 (18.9–33.4) | 15.7 (10.0–18.2) | 18.2 (7.5–22.7) | 0.12 |
| C-reactive protein, mg/L | 29.2 (10.8–69.0) | 113.1 (50.5–237.6) | 302.9 (261.5–355.8) | |
| Underlying disease | 1 (20.0) | 1 (71.4) | 1 (11.1) | 0.75 |
| Antibiotic intake in the previous 7 days | 5 (100.0) | 12 (85.7) | 6 (66.7) | 1.00 |
| Lenght of hospital stay, days (Md, IQR) | 4 (3–6) | 7 (7–8) | 7.5 (3.5–10) | 0.21 |
| Admission to PICU | 0 (0.0) | 4 (28.6) | 1 (11.1) | |
| Lenght of PICU stay, days (Md, IQR) | 0 (0.0) | 2 (0–6) | 1 (1–1) | 0.45 |
| Complications | 0 (0.0) | 2 (14.3) | 2 (22.2) | 0.80 |
| Complicated pneumonia | 0 (0.0) | 8 (57.1) | 5 (55.6) | 0.09 |
| Bacteremia | 3 (60.0) | 3 (21.4) | 1 (11.1) | 0.17 |
| Pneumonia | 2 (40.0) | 2 (14.3) | 2 (22.2) | 0.51 |
| Meningitis | 0 (0.0) | 1 (7.1) | 0 (0.0) | 1.00 |
| Sepsis | 0 (0.0) | 0 (0.0) | 1 (11.1) | 0.50 |
| Serious IPD (complicated pneumonia, meningitis, or sepsis) | 0 (0.0) | 9 (64.9) | 6 (66.7) | |
| Course of disease, sequelae or exitus | 0 (0.0) | 3 (21.4) | 2 (22.2) | 0.67 |
Results expressed as counts (%), unless stated otherwise.
Md, median; IQR, Interquartile range; SD, standard deviation; NP, nasopharyngeal; PCV13, 13-valent pneumococcal conjugate vaccine; PICU, Pediatric Intensive Care Unit; IPD, Invasive Pneumococcal Disease.
Missing values.
According to WHO recommendations.
p = 0.05 comparing Microbiota B and C.
p = 0.03 comparing Microbiota A and C; p = 0.04 comparing Microbiota A and B. The bold values means statistically significant associations with p-values < 0.05.